AR019474A1 - Compuestos 1-sustituidos de piperidina, utiles como antagonistas de los receptores 5-ht(1f), composiciones farmaceuticas formuladas con dichos compuestosy metodos para reducir la activacion de dichos receptores - Google Patents

Compuestos 1-sustituidos de piperidina, utiles como antagonistas de los receptores 5-ht(1f), composiciones farmaceuticas formuladas con dichos compuestosy metodos para reducir la activacion de dichos receptores

Info

Publication number
AR019474A1
AR019474A1 ARP990103661A ARP990103661A AR019474A1 AR 019474 A1 AR019474 A1 AR 019474A1 AR P990103661 A ARP990103661 A AR P990103661A AR P990103661 A ARP990103661 A AR P990103661A AR 019474 A1 AR019474 A1 AR 019474A1
Authority
AR
Argentina
Prior art keywords
receptors
compounds
activation
pharmaceutical compositions
reduce
Prior art date
Application number
ARP990103661A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR019474A1 publication Critical patent/AR019474A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se trata de compuestos de 5-HT(1F) de formula 1, caracterizados porque tienen la formula (I) en la que R y R son independientemente hidrogeno o hidroxi;AR1 es fenilo, naftilo, quinolinilo, isoquinolinilo, indanilo, 1,2,3,4-tetrahidronaftilo, indolilo, N-(alquil C1-C4) indolilo, benzotiazolilo, benzotienilo,benzofurilo, 2,3-dihidrobenzotienilo, 2,3-dihidrobenzofurilo, julolidinilo o dibenzofurilo, cada uno opcionalmente sustituido con uno o dos grupossustituyentes seleccionados independientementeentre el grupo compuesto por alquilo C1-6, acilo C1-6, benzoilo, alcoxi C1-6, fenoxi, alquiltio C1-6,trifluormetilo, trifluorometoxi o halo; AR2 es piridin-3-ilo, quinolin-3-ilo, isoquinolin-4-ilo o quinoxaliln-2-ilo; y sales de adicion de ácidosfarmacéuticamente aceptables de la misma. También se proponen composiciones farmacéuticas formuladas con dichos compuestos de piperidina 1-sustituida, paratratamientos que reducen la activacion de los receptores 5-HR(1F) por ejemplo en el tratamiento detrastornos debidos a estados de ansiedad.
ARP990103661A 1998-07-27 1999-07-26 Compuestos 1-sustituidos de piperidina, utiles como antagonistas de los receptores 5-ht(1f), composiciones farmaceuticas formuladas con dichos compuestosy metodos para reducir la activacion de dichos receptores AR019474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9430998P 1998-07-27 1998-07-27

Publications (1)

Publication Number Publication Date
AR019474A1 true AR019474A1 (es) 2002-02-20

Family

ID=22244418

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103661A AR019474A1 (es) 1998-07-27 1999-07-26 Compuestos 1-sustituidos de piperidina, utiles como antagonistas de los receptores 5-ht(1f), composiciones farmaceuticas formuladas con dichos compuestosy metodos para reducir la activacion de dichos receptores

Country Status (5)

Country Link
US (1) US6242450B1 (es)
EP (1) EP0976746A1 (es)
AR (1) AR019474A1 (es)
AU (1) AU5112699A (es)
WO (1) WO2000006166A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60026581T2 (de) * 1999-12-20 2006-12-28 Eli Lilly And Co., Indianapolis Indolderivate zur behandlung von depression und angstzuständen
WO2001046177A1 (en) * 1999-12-20 2001-06-28 Eli Lilly And Company Benzofuran derivatives
AU2003260882A1 (en) * 2002-09-26 2004-04-19 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
CA2548447A1 (en) * 2003-12-08 2005-06-23 Warner-Lambert Company Llc Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia
CA2903748C (en) 2013-03-12 2021-11-02 Corium International, Inc. Microprojection applicators
WO2022155152A1 (en) * 2021-01-12 2022-07-21 The Regents Of The University Of California Htr1f antagonists for improvement of beta cell survival and function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2630152A1 (de) 1976-07-05 1978-01-19 Cassella Farbwerke Mainkur Ag Derivate des 1-phenoxy-propan-2-ols- und verfahren zu ihrer herstellung
US4304912A (en) 1978-07-20 1981-12-08 Ciba-Geigy Corporation Piperidine derivatives
DE2941597A1 (de) 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
WO2000006166A1 (en) 2000-02-10
AU5112699A (en) 2000-02-21
US6242450B1 (en) 2001-06-05
EP0976746A1 (en) 2000-02-02

Similar Documents

Publication Publication Date Title
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BRPI0616799B8 (pt) derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
DE60114227D1 (de) 2,4-substituierte pyridinderivate
MA28279A1 (fr) Derives d&#39;indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
BR9915011A (pt) Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
BR9911786A (pt) Inibidores heterocìclicos de p38
BR0009297A (pt) Composto, processo para produzir o mesmo,composição farmacêutica, método paraantagonizar hormÈnio de liberação degonadotropina em um mamìfero, e, uso de umcomposto
YU18101A (sh) 4-amino supstituisani-2-supstituisani-1,2,3,4- tetrahidrohinolini kao inhibitori cetp
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
TR200400342T4 (tr) Farnezil protein transferazı önlemek için kinolin türevleri.
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
BR0015821A (pt) Derivados de pirimidina
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
AR019474A1 (es) Compuestos 1-sustituidos de piperidina, utiles como antagonistas de los receptores 5-ht(1f), composiciones farmaceuticas formuladas con dichos compuestosy metodos para reducir la activacion de dichos receptores
ES2032384T3 (es) Procedimiento para preparar derivados de carboxamidas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal